Our objective was to evaluate the role of retroperitoneal lymph node dissection (LND) in non-metastatic (M0) and metastatic (M1) renal cell carcinoma (RCC). We searched Medline, EMBASE, Web of Science and Scopus from database inception to 29 August 2017 for studies of patients who underwent partial or radical nephrectomy for M0 or M1 RCC. Two investigators independently selected studies for inclusion. Risk of bias was assessed using the NewcastleOttawa scale, Cochrane Collaboration tool and National Heart, Lung and Blood Institute Quality Assessment Tool. Random effects meta-analysis was performed for all-causemortality. The GRADE approach was used to characterize quality of evidence. A total of 51 unique studies were included in the qualitative systematic review. Risk of bias was low in 41/51 (80%) studies. LND was not associated with allcause mortality in either M0 (hazard ratio [HR] 1.02, 95% confidence interval [CI] 0.92-1.12; I 2 = 0%; four studies), M1 (HR 1.04, 95% CI 0.83-1.29; I 2 = 0%; two studies), or pooled M0 and M1 settings (HR 1.00, 95% CI 0.92-1.09; I 2 = 0%; seven studies), with no statistically significant differences according to M stage subgroups (P = 0.50). In the three studies that examined M0 subgroups with a high risk of nodal metastasis, LND was not associated with improved oncological outcomes. Studies on the association of extent of LND with survival reported inconsistent results. Meanwhile, a small proportion of patients with pN1M0 disease demonstrate durable long-term oncological control after surgery, with 10-year cancer-specific survival of 21-31%. Nodal involvement is independently associated with adverse prognosis in both M0 and M1 settings. GRADE quality of evidence was moderate or low for the outcomes examined. Although LND yields independent prognostic information, the existing literature does not support a therapeutic benefit to LND in either M0 or M1 RCC. High-risk M0 patient groups warrant further study, as a subset of patients with isolated nodal metastases experience long-term survival after surgical resection.
Introduction
Lymph node dissection (LND) has prognostic and therapeutic roles in several urological malignancies [1] [2] [3] . However, its utility in the management of RCC remains controversial [4] . Older observational studies reported a survival benefit to LND in patients undergoing nephrectomy for RCC [5] [6] [7] [8] [9] , and it has been suggested that a more extensive LND may confer a survival advantage [10] . Moreover, in a subset of patients with clinically isolated N1M0 disease, durable long-term survival has been observed after surgical resection of lymph node (LN) metastases [11] [12] [13] [14] . However, in the only randomized trial on the topic, European Organization for Research and Treatment of Cancer (EORTC) 30881, LND was not associated with oncological outcomes [15] , and several modern observational studies have likewise failed to demonstrate a survival benefit with LND, in both nonmetastatic and metastatic settings [16] [17] [18] [19] .
In light of conflicting data, there remain a number of questions regarding the role of LND in the surgical management of RCC. Most importantly, does LND provide a survival benefit in either M0 or M1 RCC, and if so, for which patient subsets? Is the extent of LND associated with therapeutic benefit? Is LND associated with increased perioperative morbidity? Can potential candidates for LND be accurately identified preoperatively? Does nodal stage provide independent prognostic information to support a predominantly staging role for LND?
We conducted the present systematic review to evaluate these important questions, which were framed as seven specific aims for the study.
Patients and Methods

Reporting
The study protocol was developed with a priori identification of seven specific aims by the co-authors, and registered on PROSPERO (registration number CRD42017070960; https:// www.crd.york.ac.uk/PROSPERO/). The systematic review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and MetaAnalysis of Observational Studies in Epidemiology (MOOSE) guidelines [20, 21] .
Research Questions/Specific Aims
Seven specific aims were developed by the co-authors to address critical questions regarding the role of LND in RCC (Supporting Information, Method S1). Our co-primary aims (PAs) were to determine whether LND was associated with improved survival among patients undergoing nephrectomy for M0 RCC (PA1) or M1 RCC (PA2).
Our secondary aims (SAs) were as follows: to evaluate the association between the extent of LND and survival in patients with RCC (SA1); to characterize the survival of patients with N1 M0 RCC after nephrectomy and either concurrent or salvage LND (SA2); to evaluate the association between LND and peri-operative morbidity (SA3); to summarize the predictive models for identifying patients at risk of pathological LN metastases (pN1; SA4); and to assess the prognostic value of N1 status in both M0 and M1 RCC (SA5).
Inclusion Criteria
We included randomized controlled trials (RCTs) and observational cohort, case-control, cross-sectional, and case series studies in humans. Animal studies, case reports, review articles, editorials, commentaries, conference abstracts, reports not subjects to peer review such as reports of data from vital statistics, dissertations and theses, and reports in languages other than English were excluded. When there was more than one report from a single study population, we preferentially included the cohorts that were larger, more contemporary, and those with longer follow-up. Multiple publications from the same study providing complementary data were combined under the heading of a single study.
Types of Participants and Exposures
We reviewed studies including patients who underwent partial or radical nephrectomy for M0 and M1 RCC. The exposure of interest for PA1, PA2 and SA3 was LND. The exposure for SA1 was the number of LNs retrieved. The exposure for SA5 was N1 stage (either cN1 or pN1). SA4 assessed predictive models that considered various clinicopathologic predictors. SA2 was descriptive with no comparison groups.
Outcome Measures
The primary outcome was all-cause mortality (ACM). Secondary outcomes included cancer-specific mortality (CSM), development of distant metastasis, risk of pN1 disease, and peri-operative morbidity.
Search Strategy
Medline, EMBASE, Web of Science and Scopus databases were searched using the OvidSP platform for studies indexed from database inception to 29 August 2017 by a professional librarian. A full search strategy is presented in the Supporting Information. Non-English-language articles were excluded upon full-text review. References from review articles, commentaries, editorials and included studies were handsearched to ensure completeness.
Study Review Methods
Study selection was performed independently by two authors (B.B. and B.G.), with disagreements resolved by consensus. Titles and abstracts were used to screen for initial study inclusion. Reports with potential to satisfy inclusion criteria and those with insufficient information to assess eligibility were subjected to full-text review.
Studies were considered relevant if they reported any of the following: an effect estimate for the association between LND and any survival outcome; an effect estimate for the association between number of LNs at LND and any survival outcome; any survival estimate for N1 M0 RCC following concurrent or salvage LND; an effect estimate for the association between LND and peri-operative morbidity; a predictive model for estimating risk of pathological LN involvement (pN1); or an effect estimate for the association between clinical or pathological nodal status and any survival outcome.
Data abstraction including evaluation of study characteristics, risk of bias and outcome measures, was performed by one author (B.G.) with independent verification by another author (B.B.).
Risk of Bias Assessment
We used the Cochrane Collaboration tool [22] , the Newcastle-Ottawa Scale [23] (adapted as described in the Supporting Information) and the National Heart, Lung and Blood Institute (NHLBI) Quality Assessment Tool [24] for risk of bias assessment for RCTs, comparative observational studies and case series, respectively. Observational comparative studies and case series with scores of <4, 4-6 and >6 were considered, having a high, intermediate and low risk of bias, respectively.
Measures of Treatment Effect
Hazard ratios (HRs) and odds ratios (ORs) were used for survival outcomes and binary outcomes (peri-operative morbidity, risk of pN1 disease), respectively. In order to limit the use of biased effect estimates, only effect estimates that were adjusted for suspected confounders were included in the analysis, except for SA3, because of the absence of any adjusted effect estimates for perioperative morbidity.
Assessment of Heterogeneity
We identified heterogeneity using the Q test, estimated it using the DerSimonian-Laird method, and quantified it using I 2 values [25] . Random-effects models were used for each of our analyses to account for potential heterogeneity.
Assessment of Reporting Bias
In our a priori protocol, we planned to assess for publication bias for outcomes with >10 included studies using funnel plots for aims examining the association of LND with survival outcomes (PA1, PA1, SA1); however, there were too few studies in each of the analyses to do this.
Data Synthesis
For primary and secondary aims, relevant study characteristics were summarized in tables. Meta-analyses were performed for primary aims using REVIEW MANAGER 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) software. We used the inverse variance technique for pooling of measures of effect. Because of the potential for clinical heterogeneity, random-effects models were used for all meta-analyses. M0 and M1 patients were analysed separately, and then pooled together if heterogeneity was low (I 2 <20%).
Results
Literature Search
The full literature search strategy is outlined in the Supporting Information. A total of 1 346 unique records were identified and underwent screening, with 224 articles selected for full-text review. After full-text review, 52 articles representing 51 unique studies were included in the qualitative systematic review, of which seven were included in the meta-analysis (Fig. 1) . The number of studies included for each specific aim are as follows: PA1/PA2: nine reports representing eight unique studies [5, [15] [16] [17] [18] [19] [26] [27] [28] ; SA1: six studies [10, 17, [29] [30] [31] [32] (of which two represented separate analyses of the same dataset) [10, 32] ; SA2: 15 studies [11] [12] [13] [14] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] (of which one single-institutional study was included in a multi-institutional study) [11, 38] 
Description of Included Studies
Characteristics of the included studies are presented in Table S1 . One study was an RCT [15] , two were secondary analyses of RCTs [27, 28] (including a secondary analysis of the one RCT) [15] , and the others were observational studies.
The majority of studies were single-institutional reports from Europe and the USA, with several multi-institutional collaborations and analyses of population-based datasets. Most studies included patients with any clinical tumour and nodal stage, although there was substantial heterogeneity in study cohorts and disease risk, as reflected in a wide distribution of pathological tumour and nodal stages. Likewise, median follow-up duration varied widely (range: 8-151 months).
Risk of Bias Assessment
Risk of bias was low for the majority of observational cohort studies, as determined according to the Newcastle-Ottawa Scale (Table S2 ). Most studies selected exposed (LND) and non-exposed (no LND) cohorts from a representative population, with clear ascertainment of LND status using surgical or pathology reports, and survival outcomes (i.e. mortality) were, by design, absent at the start of study. Outcomes were generally reliably assessed using medical records or population-based registries, with adequate duration of follow-up. Although many studies adjusted for the most important confounding factor (pT stage), inadequate statistical adjustment remained the greatest potential source of bias in many studies. The one RCT in this systematic review was considered to have a low risk of bias in all domains according to the Cochrane Collaboration tool for assessing risk of bias [15, 27] . Twelve case series were included only in SA2. Quality assessment for these studies was performed according to the NHLBI Quality Assessment Tool for Case Series Studies and is summarized in Table S3 .
Primary Aim 1: Association of Lymph Node Dissection with Survival Among Patients with M0 RCC
Four studies examined the overall associations of LND with survival outcomes in non-metastatic RCC (Table 1) [ [15] [16] [17] 28] . The incidence of LN metastases in these studies was low, ranging from 4% to 8%. The only RCT to examine this topic (EORTC 30881) reported no difference in oncologic outcomes with LND [15] . Two recent observational studies similarly reported no significant association, one of which utilized extensive statistical adjustment [16, 17] . In a fourth study which reported a secondary analysis of a trial of adjuvant therapy in high-risk M0 RCC (ECOG E2805), LND was not associated with improved overall survival (OS) [28] .
Three studies examined the association between LND and survival specifically in patients with M0 RCC at higher risk of node-positive disease (Table 2 ) [17, 27, 28] . In one of these, LND was not associated with improved oncological outcomes among patients with preoperative radiographic lymphadenopathy or across increasing probability thresholds for pN1 disease from 0.05 to 0.50 [17] . In another study in which the authors conducted a secondary analysis of EORTC 30881, LND was not associated with improved survival among patients with cT3 tumours [27] . In the third such study, LND was not associated with improved OS among patients with high-risk (pT1bG3-4N0/NX, pT2-4N0/NX, pTanyN+) M0 RCC enrolled in a clinical trial (ECOG E2805) [28] . Two studies examined the association of LND with survival among patients with metastatic RCC undergoing cytoreductive nephrectomy, both reporting no difference in oncologic outcomes with LND in the overall cohort (Table 1) [18, 19] . The incidence of LN metastases was 24-33%. One study further examined patients at increased risk of LN metastases, reporting no survival benefit to LND among patients with cN1 disease or across increasing probability thresholds for LN metastases from 0.20 to 0.80 (Table 2 ) [19] .
Association of Lymph Node Dissection with Survival Among Studies with Pooled M0 and M1 RCC cohorts
Two studies examined cohorts that included both M0 and M1 RCC (Tables 1 and 2 ) [5, 26] . In one of these, LND was not associated with survival in the overall cohort [26] . In the other such study, LND was not associated with survival among patients without radiographic lymphadenopathy (cN1), but the authors did report an OS benefit among cN1 patients, although statistical adjustment was limited [5] .
Meta-analysis of the Association of Lymph Node Dissection with Survival in M0 and M1 RCC
We further conducted a meta-analysis to evaluate the association of LND with ACM among patients with M0 or M1 RCC. Seven studies were included in the meta-analysis (Fig. 2) [15] [16] [17] [18] [19] 26] . The overall pooled HR was 1.00 (95% CI 0.92-1.09; I 2 = 0%), with no statistically significant differences by M stage subgroup (P = 0.50). Among studies examining M0 RCC, the pooled HR was 1.02 (95% CI 0.92-1.12; I 2 = 0%), while among studies examining M1 RCC, the pooled HR was 1.04 (95% CI 0.83-1.29; I 2 = 0%). There was an insufficient number of studies to conduct a meta-analysis of other oncological endpoints or to examine high-risk patient subsets.
Secondary Aim 1: Association of Extent of Lymph Node Dissection with Survival Outcomes
Six studies examined the association of extent of LND with survival (Table 3) [10, 17, [29] [30] [31] [32] . Among four studies that examined this question in M0 RCC, one reported no association of extent of LND with oncologic outcomes [17] , while another examining only pT4 M0 RCC reported improved survival with greater extent of LND [29] . Two other studies represent separate analyses of the same cohort, with one noting improved survival with more extended LND among patients with LN metastases [10] , while the other found no association between LND and CSM when missing data were handled using different statistical techniques [32] . Among two studies that included both M0 and M1 RCC, one reported that more extended LND was associated with reduced rates of metastatic progression and CSM among specific patient subgroups [30] , while the other reported increased CSM with more extended LND [31] .
Secondary Aim 2: Survival Outcomes of Patients with pN1M0 RCC
Twelve studies reported survival outcomes for clinically isolated (pN1M0) LN metastatic RCC identified at the time (Table 4) [12] [13] [14] [33] [34] [35] [36] [37] 39, 40, 42, 43] . Fiveyear cancer-specific survival (CSS) was low, ranging from 22% to 39%. The majority of such patients appeared to have occult systemic disease at the time of nephrectomy, with median time to metastatic progression of only 4.2 months in one report [13] . However, the few studies with long-term data noted durable CSS in a small subset of patients (21-31% at 10 years). OS outcomes were similar to CSS.
Three studies reported on outcomes following salvage LND for isolated retroperitoneal nodal recurrence (Table 4 ) [11, 38, 41] . Five-year CSS ranged from 35% to 74%. In one single-institutional report [11] that was included in a subsequent multi-institutional collaboration [38] , the authors noted that survival after resection of isolated retroperitoneal recurrence was similar to that following isolated LN metastases at the time of nephrectomy.
Secondary Aim 3: Association of Lymph Node Dissection with Peri-operative Morbidity
Five studies examined the association of LND with perioperative morbidity, although none provided adjusted effect estimates (Table 5 ) [5, 15, 28, 44, 45] . The probability of any peri-operative complication ranged from 17% to 26%, and no statistical comparisons were provided across LND groups in three studies [5, 15, 44] . In another study of patients undergoing cytoreductive nephrectomy, LND was not associated with 30-day complications on univariable analysis (OR 1.76, 95% CI 0.81-3.82; P = 0.15) [45] . Similarly, in a secondary analysis of the ECOG E2805 trial, there were no differences in unadjusted complication rates according to performance of LND [28] .
Although no formal statistical comparisons were provided, descriptive comparisons revealed no differences in estimated blood loss, blood transfusion, operating time, or length of hospital stay in two studies [5, 44] . In another study, LND was not associated with prolonged hospitalization on univariable analysis (OR 1.65, 95% CI 0.93-2.95; P = 0.09) [45] .
Secondary Aim 4: Predictive Models for Identifying Patients at Risk of Lymph Node Metastasis
Ten studies reported on multivariable models predicting probability of pN1 disease (Table 6 ) [18, [46] [47] [48] [49] [50] [51] [52] [53] [54] . The multivariable models included nomograms in three studies [46, 48, 52] , risk scores in three studies [47, 50, 51] , and multivariable regression models in four studies [18, 49, 53, 54] . The most common covariates associated with pN1 disease included tumour stage, tumour size and radiographic lymphadenopathy (cN1). Eighteen studies evaluated the prognostic value of cN1 or pN1 status using multivariable analyses (Table 7 ) [18, 26, 29, 39, 40, 42, [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] . The presence of pathological LN metastases (pN1) was independently associated with increased CSM [26, 29, 39, 42, 54, 57, 59, 60, [63] [64] [65] and ACM [26, 55, 61] in both M0 and M1 settings. Similarly, the presence of radiographic lymphadenopathy (cN1) was independently associated with increased CSM and ACM in M0 and M1 RCC [18, 54, 58] .
Overall Assessment of Quality of Evidence
The GRADE summary of evidence ratings were moderate for PA1 and SA5, but low for the other aims (Table 8) .
Discussion
In this systematic review, we examined seven critical questions to address the role of LND in the contemporary surgical management of RCC. In the first meta-analysis on the topic, LND was not associated with a survival benefit in either non-metastatic or metastatic RCC, without meaningful heterogeneity (I 2 = 0%) across M-stage groups. It is important to consider that most M0 studies have had a low overall incidence of LN metastases. It is therefore possible that LND may provide a survival benefit to high-risk patient subsets, although in the few studies that examined high-risk groups, such as those with preoperative radiographic lymphadenopathy (cN1), LND still did not appear to provide a survival advantage. Nonetheless, the small number of such studies identifies an important knowledge gap for future investigations. A RCT of LND in high-risk patients would be ideal to answer this question, although given the rarity of LN metastases in contemporary RCC, it may be difficult to accrue sufficient numbers of patients to such a study.
Several studies that evaluated LND in M0 RCC were excluded from this systematic review because they only provided unadjusted associations of LND with oncological outcomes [6, 8, 31, [66] [67] [68] . Several of these studies reported improved survival among patients who underwent LND [6, 8] , while others did not observe a survival benefit to LND [31, [66] [67] [68] . Two studies that examined LND in M1 RCC did not report adjusted effect estimates and were also excluded from this systematic review [7, 69] . In one study, patients who 
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© 2018 The Authors BJU International © 2018 BJU International underwent complete LND had improved unadjusted survival compared with those who underwent partial LND [7] . In another study, the survival of patients with completely resected lymphadenopathy was similar to that of patients without lymphadenopathy [69] . In the absence of statistical adjustment for important confounders, reliable causal inference cannot be made from such data.
The evidence for an association between extent of LND (as measured by number of LNs removed) and oncological outcomes is mixed. Two studies from the same group have reported improved survival among specific patient subsets in both M0 and M1 RCC [29, 30] , while other studies that have examined all patients have not observed a survival benefit [17, 31, 32] . Given that the number of LNs retrieved may be an indicator of overall surgical quality rather than being causally related, further validation is required, particularly in the absence of an overall therapeutic benefit to LND, as discussed above.
Several studies excluded from this review provided unadjusted estimates for the association of extent of LND with survival among patients with node-positive (pN1) RCC in either M0 [13, 34, 42] or M1 settings [64] . Extent of LND was not associated with survival in any of these studies.
A number of studies have described the natural history of pN1 disease after either concurrent or salvage LND. After primary LND for pN1M0 disease, a minority of patients demonstrate long-term survival, with 10-year CSS of 21-31%. Few studies have examined salvage LND for pN1M0 disease, although CSS appears to be similar overall to CSS after primary LND. These results reinforce observations from other studies that clinically isolated pN1 disease is often associated with occult distant metastatic disease [4, 5, 70] .
There are remarkably few data regarding the incremental peri-operative morbidity of LND. Of five studies that evaluated peri-operative morbidity, none provided adjusted effect estimates and many did not provide statistical ACM, all-cause mortality; CSM, cancer-specific mortality; CSS, cancer-specific survival; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio; LN, lymph node; LND, lymph node dissection; MFS, metastasis-free survival; MVA, multivariable analysis; NR, not reported; OS, overall survival; PFS, progression-free survival. *Single-institutional study also included in multi-institutional study by Russel (2016) [38] . † Survival estimate for pN+ V0. [28] NR NR NR NR Overall: 14.2% vs 13.4%, P = 0.63 Wound infection: 1.3% vs 1.2%; P = 1.00 Wound dehiscence/fistula: 0.4% vs 0.7%; P = 0.55 Pneumonia: 1.0% vs 0.6%; P = 0.28 Cardiopulmonary: 1.1% vs 1.1%; P = 1.00 Haemorrhage: 0.6% vs 1.1%; P = 0.32 Heart/lung bypass: 0.4% vs 0.1%; P = 0.14 Renal failure: 0.6% vs 0.5%; P = 0.75 Other: 10.4% vs 9.8%; P = 0.64 [5] M0 
<0.001
ACM, all-cause mortality; CSM, cancer-specific mortality; HR, hazard ratio; aHR, adjusted hazard ratio; LN, lymph node; MVA, multivariable analysis; NS, nonsignificant. comparisons across LND groups. Thus, while no study reported increased peri-operative morbidity with LND, the GRADE quality of evidence was low. Further studies are critical to evaluate whether LND is associated with incremental morbidity among patients undergoing nephrectomy, particularly if LND is to serve a predominantly staging role in the absence of a demonstrated survival benefit.
Preoperative identification of patients at risk for LN involvement is important to select candidates for LND. To this end, various studies have reported multivariable models for predicting pN1 disease, including three nomograms [46, 48, 52] and two risk scores [47, 51] with this purpose.
Although each model appears to perform well in development cohorts, only one of the predictive tools has been externally validated [47, 50] . Such models have clinical utility even in the absence of a therapeutic benefit to LND. For example, they may be used to identify candidates for staging LND, to improve preoperative risk stratification, and to identify candidates for clinical trials. The most frequent predictors of pN1 disease were tumour stage, tumour size, and radiographic lymphadenopathy.
Preoperative radiographic lymphadenopathy has historically been considered to correlate poorly with risk of pathological nodal involvement. In a seminal paper, Studer et al. [71] reported that a 1-cm size threshold for radiographic lymphadenopathy was associated with benign/inflammatory changes in 58% of cases [71] ; however, a recent study noted that LN short axis diameter is linearly related to risk of pN1 disease, reinforcing the findings of Studer et al. that lymphadenopathy has a low positive predictive value at a 1-cm threshold, and suggesting that greater LN short axis diameter thresholds are associated with higher probability of LN involvement [51] .
Nodal stage appears to provide important prognostic information, as pN1 status is independently associated with worse survival in both M0 and M1 RCC in numerous studies. A number of other studies have reported unadjusted estimates for the prognostic value of N stage. The majority of such studies have noted an adverse prognosis with radiographic lymphadenopathy or pathologic LN metastases, both in M0 and M1 settings [5, 9, 16, 18, 19, 31, 35, 46, 47, 69, 70, 72] , while a minority have not supported this association [73] . These observations support a staging role for LND, as pathological assessment of nodal stage may identify patients for closer postoperative surveillance or consideration of enrolment into adjuvant therapy trials [74] .
It is important to reconcile the absence of a survival benefit to LND in the literature with the underlying biological plausibility supporting it. Indeed, the theoretical basis for a survival benefit to LND in RCC is straightforward; in the non-metastatic setting, resection of all sites of disease (including nodal) may be curative, while in the metastatic setting, cytoreduction of nodal disease may improve response to systemic therapy [75] and reduce tumour-mediated immunological suppression. However, as discussed above, LN involvement is associated with occult systemic disease in the majority of clinically non-metastatic cases. This may in part be related to retroperitoneal lymphatic drainage patterns; direct lymphovenous communications have been described, including lymphatic drainage into the renal vein, inferior vena cava and through the thoracic duct, into the subclavian vein [76] . These observations may explain the predominantly hematogeneous route of dissemination attributed to RCC. In the metastatic setting, LN disease has been consistently reported as an adverse prognostic feature, and has been associated with adverse tumour biology [13, 62] . Furthermore, it is possible that the small subset of patients with LN metastases who demonstrate durable survival after surgical resection may reflect more indolent tumour biology with a prolonged natural history [13, 77] .
Several limitations warrant mention. First, all systematic reviews must accept the limitations of the individual contributing studies. Given that almost all included studies were observational, selection bias and residual confounding cannot be excluded. Furthermore, there are limited data evaluating the impact of LND on survival in patients at increased risk of LN metastases, and we were unable to conduct a meta-analysis examining high-risk patient groups because of the heterogeneous definitions across studies. It is possible that certain high-risk patient subsets may derive a survival benefit from LND. In addition, there are limited data on the role of LND after the introduction of targeted systemic therapies and PD-L1 inhibitors. Finally, we were unable to exclude publication bias for outcomes evaluating the survival benefit of LND.
In conclusion, the existing literature does not support a survival benefit with LND in either M0 or M1 RCC, although further studies are needed to draw definitive conclusions in high-risk M0 patients. A small subset of patients with isolated nodal metastases experience long-term survival after surgical resection. Nodal involvement is independently associated with adverse prognosis in both M0 and M1 settings. LND may therefore play an important staging role in the contemporary surgical management of RCC.
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